Chemistry:Potrasertib
From HandWiki
Potrasertib is an investigational new drug that is being evaluated by IMPACT Therapeutics for the treatment of advanced solid tumors. It is oral inhibitor of WEE1 kinase, a key regulator of cell cycle checkpoints.[1][2]
References
- ↑ "IMP 7068". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800058368.
- ↑ "An update of predictive biomarkers related to WEE1 inhibition in cancer therapy". Journal of Cancer Research and Clinical Oncology 150 (1): 13. January 2024. doi:10.1007/s00432-023-05527-y. PMID 38231277.
 |  |
